Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by james700on Apr 24, 2019 1:03pm
260 Views
Post# 29664777

Letter sent to Prometic

Letter sent to Prometic
We have 736M outstanding shares. The latest round of financing is a huge disrespect to CURRENT SHAREHOLDERS. This 20 to 1 share purchase effectively means we as share holders are buying a share for $0.3042 per share. If everyone was ALLOWED to buy shares at this price we would raise $223M. Instead, you have allowed Thomvest to convert their debt at $0.01521, resulting in 15B shares issued. You are only allowing 33% of CURRENT SHAREHOLDERS to purchase shares at this price, effectively guaranteeing Thomvest majority control of 72.5% for $229M. Resulting in only 25% of company 4.9B shares compared to 20B shares to be issued. Interesting that 66% of shareholders will have their holdings reduced to 2.5% of the company. 491M shares compared to 20B shares to be issued. Legal action will be pursued if the $75M cap is maintained for current shareholders. Ask yourself, what would you do if you were a retail investor and you were treated like this by a company you have been invested in since 2012. Please explain how you can treat your shareholders like this.
Bullboard Posts